Michael N. Badminton

Michael N. Badminton

Auto-generated profile, based on publicly available information

Michael N. Badminton

School of Medicine Cardiff University Cardiff UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2017
Verified
Book Chapter
Open access
PDF file
DSDanja Schulenburg-Brand
Danja Schulenburg-Brand
TGTricia Gardiner
Tricia Gardiner
SGSimon Guppy
Simon Guppy
DRDavid Rees
David Rees
PSPenelope Stein
Penelope Stein
MBMichael Badminton
Michael Badminton
Severe recurrent acute attacks of porphyria have traditionally been treated with either prophylactic human haemin or gonadorelin analogues (GnA) in females. Evidence on the most effective treatment for this patient subgroup is lacking. This audit surveyed the use of prophylactic GnA in the UK. Twenty female patients (who experienced between 2 and 45 acute attacks of porphyria requiring hospitalisation and treatment with human haemin prior to GnA prophylaxis) were included in the audit. Data was retrospectively collected based on patient history and case review. Twenty three treatment courses were given lasting a median period of 12 months. Monthly subcutaneous Goserelin was most commonly used. In three patients in whom timing with the menstrual cycle was not considered, an acute attack occurred after initiation of the first dose. The majority of patients experienced oestrogen deficiency symptoms during treatment. Fifty percent of the prescribed courses of GnA resulted in a degree of clinical benefit. This successfully treated group experienced between 3 and 20 acute attacks prior to and between 0 and 6 acute attacks during GnA treatment. The audit revealed large variation in practice in the United Kingdom regarding indication, duration of treatment, specific drug used and management of side effects. In view of the limited treatment options available for this cohort and the mixed outcome successes reported, we believe it is reasonable for porphyria specialists to continue offering GnA treatment to women with severe recurrent debilitating acute attacks of porphyria associated with the menstrual cycle, and we propose best practice guidelines to standardise management.

1 November 2019 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
BCBrenden Chen
Brenden Chen
SWSharon Whatley
Sharon Whatley
MBMichael Badminton
Michael Badminton
AAAasne K. Aarsand
Aasne K. Aarsand
KAKarl Elmo Anderson
Karl Elmo Anderson
RDRobert J. Desnick
Robert J. Desnick

20 May 2024 in Liver International
Verified
Journal Article
Closed access
MBMichael N. Badminton
Michael N. Badminton
KAKarl E. Anderson
Karl E. Anderson
JDJean‐Charles Deybach
Jean‐Charles Deybach
PHPauline Harper
Pauline Harper
SSSverre Sandberg
Sverre Sandberg
GEGeorge H. Elder
George H. Elder

9 September 2024 in Liver International
Verified
Journal Article
Closed access
AFAntonio Fontanellas
Antonio Fontanellas
MAMatías A. Avila
Matías A. Avila
JDJean‐Charles Deybach
Jean‐Charles Deybach
MBMichael N. Badminton
Michael N. Badminton

17 April 2026 in Liver International
Verified
Journal Article
Closed access
PDF file
CBCarl M. Baravelli
Carl M. Baravelli
SSSverre Sandberg
Sverre Sandberg
MHMarte H. Hammersland
Marte H. Hammersland
PHPauline Harper
Pauline Harper
MBMichael N. Badminton
Michael N. Badminton
AAAasne K. Aarsand
Aasne K. Aarsand